Imprimis Pharmaceuticals (NASDAQ:IMMY)’s share price reached a new 52-week low during trading on Tuesday , ARN reports. The stock traded as low as $5.91 and last traded at $6.00, with a volume of 42,490 shares trading hands. The stock had previously closed at $6.75.
Several research firms have commented on IMMY. Zacks upgraded Imprimis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, September 28th. Sterne Agee CRT began coverage on Imprimis Pharmaceuticals in a report on Thursday, July 23rd. They issued a “buy” rating and a $10.00 target price for the company.
The firm has a 50 day moving average price of $7.00 and a 200 day moving average price of $7.82. The firm’s market capitalization is $57.56 million.
Imprimis Pharmaceuticals (NASDAQ:IMMY) last posted its earnings results on Wednesday, August 12th. The specialty pharmaceutical company reported ($0.39) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by $0.06. The company earned $2 million during the quarter, compared to analyst estimates of $2.13 million. Analysts anticipate that Imprimis Pharmaceuticals will post ($1.44) EPS for the current year.
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) is a pharmaceutical company. The Company focuses on developing and commercializing compounded drug therapies and making these therapies available to physicians and patients. It owns, markets and sells a portfolio of combination formulations in ophthalmology and urology. Its ophthalmology formulation portfolio includes Dropless Therapy and LessDrops formulations, which serve the eye drop market. Its Defeat IC campaign includes a compounded formulation for patients suffering from interstitial cystitis. It makes, dispenses and sells its compounded formulations, as well as other non-proprietary products, through its compounding pharmacies Pharmacy Creations, LLC (Pharmacy Creations) and Park. Its pharmacies also dispense prescriptions for complementary compounded formulations within the ophthalmology and urology therapeutic areas, as well as other compounded formulations in other therapeutic areas for an individually identified patient.